Guardant Health (GH) Stock Overview
A precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GH Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$92.41 |
| 52 Week High | US$95.88 |
| 52 Week Low | US$21.85 |
| Beta | 1.53 |
| 1 Month Change | 47.90% |
| 3 Month Change | 123.10% |
| 1 Year Change | 322.35% |
| 3 Year Change | 105.13% |
| 5 Year Change | -21.30% |
| Change since IPO | 186.99% |
Recent News & Updates
Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts
Oct 31Guardant Health, Inc. (NASDAQ:GH) Stocks Shoot Up 48% But Its P/S Still Looks Reasonable
Oct 31
Recent updates
Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts
Oct 31Guardant Health, Inc. (NASDAQ:GH) Stocks Shoot Up 48% But Its P/S Still Looks Reasonable
Oct 31Guardant Health, Inc. (NASDAQ:GH) Looks Just Right With A 26% Price Jump
Jun 19
Medicare Coverage Of Reveal And Shield's FDA Approval Will Expand Market Reach
Achieving ASP goals and expanding Medicare coverage will drive revenue growth through higher pricing and increased test volumes.Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Feb 13Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 43% Share Price Bounce
Jan 22Guardant Health: Remains Risky Despite SHIELD's Early Success
Jan 21Why Guardant Health, Inc. (NASDAQ:GH) Could Be Worth Watching
Dec 31Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Shareholder Returns
| GH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 33.3% | -5.0% | 0.5% |
| 1Y | 322.3% | -18.1% | 19.8% |
Return vs Industry: GH exceeded the US Healthcare industry which returned -15.3% over the past year.
Return vs Market: GH exceeded the US Market which returned 19% over the past year.
Price Volatility
| GH volatility | |
|---|---|
| GH Average Weekly Movement | 10.9% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,010 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.
Guardant Health, Inc. Fundamentals Summary
| GH fundamental statistics | |
|---|---|
| Market cap | US$9.01b |
| Earnings (TTM) | -US$398.79m |
| Revenue (TTM) | US$902.57m |
Is GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GH income statement (TTM) | |
|---|---|
| Revenue | US$902.57m |
| Cost of Revenue | US$327.11m |
| Gross Profit | US$575.46m |
| Other Expenses | US$974.25m |
| Earnings | -US$398.79m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | 63.76% |
| Net Profit Margin | -44.18% |
| Debt/Equity Ratio | -314.4% |
How did GH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 17:49 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guardant Health, Inc. is covered by 33 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |